Document Detail


A prospective study of cutaneous adverse events induced by low-dose alpha-interferon treatment for malignant melanoma.
MedLine Citation:
PMID:  14730237     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: alpha-Interferon is associated with numerous cutaneous side effects, but the accurate incidence of these complications is not clearly known. OBJECTIVES: A prospective study was designed to evaluate the incidence and clinical pattern of cutaneous side effects in a cohort of patients receiving adjuvant therapy with low-dose interferon for malignant melanoma. MATERIAL AND METHODS: A cohort of 33 patients with stage IIA and IIB melanoma treated with low-dose alpha-interferon (3 MIU 3 times a week for 18 months) were prospectively enrolled in a single-center study. The patients responded to a questionnaire on their medical history and were systematically examined for any cutaneous lesions before treatment and every 3 months afterwards. RESULTS: 29/33 patients (87%) experienced 1 or more cutaneous side effects. The most frequent was hair loss and occurred in 16 cases (48.4%). Hair discoloration was noted in 6 cases (18%). Eczematous reactions at injection sites or at remote sites were observed in 13 patients (39%). Pruritus occurred in 10 cases (30%). Xerostomia, Raynaud's phenomenon or livedo reticularis were observed in 10 patients, associated with an increase in circulating autoantibody titer in 2 cases. Some rare side effects were observed: urticaria (1 case) or angioedema (1 case), worsening of preexisting seborrheic dermatitis (3 cases), herpetic recurrence (2 cases), pityriasis versicolor (1 case), worsening of recurrent buccal aphthous ulcer (1 case) and vitiligo (1 case). CONCLUSION: Cutaneous adverse events during adjuvant immunotherapy of melanoma with low-dose alpha-interferon seem to be frequent but do not result in treatment discontinuation. A good awareness of these side effects may be useful for a more accurate survey and clinical management of patients receiving this treatment.
Authors:
B Guillot; L Blazquez; D Bessis; O Dereure; J J Guilhou
Related Documents :
17613267 - Skin and joint infection by mycobacterium chelonae: rescue treatment with interferon ga...
7537527 - Clinical and laboratory effects of long-term administration of hydroxyurea to patients ...
20453627 - Randomized controlled trial of trained patient-nominated treatment supporters providing...
9683207 - Maintenance therapy after quadruple induction therapy in hiv-1 infected individuals: am...
21656867 - 3-dimensional ultrasonographic assessment of the compression effect on urethra followin...
10650507 - New technologies in transurethral resection of the prostate.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Dermatology (Basel, Switzerland)     Volume:  208     ISSN:  1018-8665     ISO Abbreviation:  Dermatology (Basel)     Publication Date:  2004  
Date Detail:
Created Date:  2004-01-19     Completed Date:  2004-06-08     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9203244     Medline TA:  Dermatology     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  49-54     Citation Subset:  IM    
Copyright Information:
Copyright 2004 S. Karger AG, Basel
Affiliation:
Service de Dermatologie, Hôpital Saint-Eloi, CHU de Montpellier, Montpellier, France. b-guillot@chu-montpellier.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Antineoplastic Agents / adverse effects*,  therapeutic use
Female
Head and Neck Neoplasms / drug therapy*
Humans
Interferon-alpha / adverse effects*,  therapeutic use
Male
Melanoma / drug therapy*
Middle Aged
Prospective Studies
Pruritus / chemically induced
Skin Diseases / chemically induced*
Xerostomia / chemically induced
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Interferon-alpha

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Interferon alpha as adjuvant postsurgical treatment of melanoma: a meta-analysis.
Next Document:  Single-dose fluconazole versus itraconazole in pityriasis versicolor.